Enzyme Inhibition in Drug Discovery and Development (Hardcover)
Language: English
Published by John Wiley & Sons Inc, New York, 2010
- First Edition
- Hardcover
- New

Seller: CitiRetail, Stevenage, United KingdomCitiRetail
AbeBooks seller since June 29, 2022
Condition: New
US$ 266.76
Quantity: 1 available
Add to basketItem description from seller
Hardcover. The science and applied approaches of enzyme inhibition in drug discovery and development Offering a unique approach that includes both the pharmacologic and pharmaco-kinetic aspects of enzyme inhibition, Enzyme Inhibition in Drug Discovery and Development examines the scientific concepts and experimental approaches related to enzyme inhibition as applied in drug discovery and drug development. With chapters written by over fifty leading experts in their fields, Enzyme Inhibition in Drug Discovery and Development fosters a cross-fertilization of pharmacology, drug metabolism, pharmacokinetics, and toxicology by understanding the "good" inhibitionsdesirable pharmacological effectsand "bad" inhibitionsdrugdrug interactions and toxicity. The book discusses: The drug discovery process, including drug discovery strategy, medicinal chemistry, analytical chemistry, drug metabolism, pharmacokinetics, and safety biomarker assessment The manipulations of drug metabolizing enzymes and transporters as well as the negative consequences, such as drugdrug interactions The inhibition of several major drug target pathways, such as the GPCR pathway, the NFkB pathway, and the ion channel pathway Through this focused, single-source reference on the fundamentals of drug discovery and development, researchers in drug metabolism and pharmacokinetics (DMPK) will learn and appreciate target biology in drug discovery; discovery biologists and medicinal chemists will also broaden their understanding of DMPK. This book covers the science and approaches of enzyme inhibition applied in drug discovery and drug development, including both pharmacology and pharmacokinetic aspects of enzyme inhibition. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.…
Seller Inventory # 9780470281741
- Title
- Enzyme Inhibition in Drug Discovery and Development (Hardcover)
- Author
- Chuang Lu
- Publisher
- John Wiley & Sons Inc, New York
- Publication year
- 2010
- Condition
- new
- Binding
- Hardcover
- Language
- English
- ISBN 10
- 047028174X
- ISBN 13
- 9780470281741
- Edition
- 1st Edition
Offering a unique approach that includes both the pharmacologic and pharmaco-kinetic aspects of enzyme inhibition, Enzyme Inhibition in Drug Discovery and Development examines the scientific concepts and experimental approaches related to enzyme inhibition as applied in drug discovery and drug development.
With chapters written by over fifty leading experts in their fields, Enzyme Inhibition in Drug Discovery and Development fosters a cross-fertilization of pharmacology, drug metabolism, pharmacokinetics, and toxicology by understanding the "good" inhibitions―desirable pharmacological effects―and "bad" inhibitions―drug–drug interactions and toxicity. The book discusses:
-
The drug discovery process, including drug discovery strategy, medicinal chemistry, analytical chemistry, drug metabolism, pharmacokinetics, and safety biomarker assessment
-
The manipulations of drug metabolizing enzymes and transporters as well as the negative consequences, such as drug–drug interactions
-
The inhibition of several major drug target pathways, such as the GPCR pathway, the NFkB pathway, and the ion channel pathway
Through this focused, single-source reference on the fundamentals of drug discovery and development, researchers in drug metabolism and pharmacokinetics (DMPK) will learn and appreciate target biology in drug discovery; discovery biologists and medicinal chemists will also broaden their understanding of DMPK.
"Synopsis" may belong to another edition of this title.
About the Author
Albert P. Li, PhD, is the President and CEO of In Vitro ADMET Laboratories, LLC and Advanced Pharmaceutical Sciences, Inc., and the cofounder, Chairman, and CSO of the ADMET Group. His experience spans over twenty-five years in the drug development industry, with over 150 publications. He is the editor of several books, including Drug–Drug Interactions in Pharmaceutical Development, published by Wiley.
"About the title" may belong to another edition of this title.
CitiRetail
Stevenage, United Kingdom
AbeBooks seller since June 29, 2022
Shipping rates from United Kingdom to U.S.A.
| Item | 7 to 14 business days | 7 to 60 business days |
|---|---|---|
| First item | US$ 50.04 | US$ 50.04 |
Payment methods
Store description
Online business
Seller's business information
ABC BOOKS LIMITED
10 John Street
London, United Kingdom WC1N 2EB
Terms of sale
Orders can be returned within 30 days of receipt.
Shipping terms
Please note that titles are dispatched from our US, Canadian or Australian warehouses. Delivery times specified in shipping terms. Orders ship within 2 business days. Delivery to your door then takes 7-14 days.